Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) Patents (Class 424/133.1)
-
Patent number: 11613785Abstract: The present invention generally relates to a method of diagnosing, prognosing and treating prostate cancer patients. Particularly, the present invention relates to a method of selecting patients with castration resistant prostate cancer (CrPC) for combination therapy comprising a selective dipeptidyl peptidase inhibitor and a PD-1 axis antagonist. The present invention provides a computational approach to identifying potential patients for CrPC. The present invention also relates to a method of treating castration resistant prostate cancer (CrPC) patients with said combination therapy.Type: GrantFiled: January 9, 2018Date of Patent: March 28, 2023Assignee: OnkosXcel Therapeutics, LLCInventors: Krishnan Nandabalan, Luca Rastelli
-
Patent number: 11607452Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.Type: GrantFiled: December 11, 2019Date of Patent: March 21, 2023Assignee: NeoTX Therapeutics Ltd.Inventors: Asher Nathan, Michal Shahar
-
Patent number: 11607419Abstract: The present invention concerns a compound having the following formula (I): wherein: —A is in particular —N(R?a)—C(?O)—R, R?a being H or a (C1-C6)alkyl group, and R being preferably a group having the following formula (II): —X is in particular chosen from the group consisting of: —SO2—N(R?b)—, R?b being H or a (C1-C6)alkyl group, —N(R?b)—SO2—, R?b being H or a (C1-C6)alkyl group, —CO—NH—, and —NH—CO—, for use for the treatment of pathologies characterized by bronchoconstriction, such as asthma.Type: GrantFiled: June 6, 2018Date of Patent: March 21, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NANTES, CHU NANTESInventors: Vincent Sauzeau, Gervaise Loirand, Jacques Lebreton, Arnaud Tessier, Agnes Quemenier
-
Patent number: 11596652Abstract: Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. Further, anti-inflammatory cytokine release may be reduced. In certain instances, compositions may include additional agents.Type: GrantFiled: May 28, 2020Date of Patent: March 7, 2023Assignee: ENLIVEX THERAPEUTICS R&D LTDInventors: Shai Novik, Dror Mevorach
-
Patent number: 11591599Abstract: This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and/or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer.Type: GrantFiled: April 3, 2018Date of Patent: February 28, 2023Assignees: Fundació Institut de Recerca Biomèdica (IRB Barcelona), Institució Catalana de Recerca i Estudis AvançaisInventors: Roger Gomis, Anna Arnal, Maria Tarragona, Milica Pavlovic, Evarist Planet
-
Patent number: 11590217Abstract: Cancer is treated via a coordinated treatment regimen that use various compounds and compositions that employ prime-boost vaccination in combination with immune modulatory treatment and biasing of an immune response towards a Th1 profile.Type: GrantFiled: April 22, 2019Date of Patent: February 28, 2023Assignee: NantCell, Inc.Inventors: Shahrooz Rabizadeh, Patrick Soon-Shiong
-
Patent number: 11590213Abstract: Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection.Type: GrantFiled: December 18, 2019Date of Patent: February 28, 2023Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Harvey Cantor, Hye-Jung Kim, Jianmei Wu Leavenworth
-
Patent number: 11591371Abstract: Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a neonatal receptor (FcRn); an influenza HA protein; and a trimerization domain. Disclosed are compositions comprising one or more of the peptides described herein. Disclosed are nucleic acid sequences capable of encoding any one of the peptides described herein. Disclosed are methods for eliciting a protective immune response against influenza comprising administering to a subject an effective amount of a composition comprising a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; an influenza HA protein; and a trimerization domain, wherein the administering is to a mucosal epithelium.Type: GrantFiled: April 2, 2019Date of Patent: February 28, 2023Assignee: UNIVERSITY OF MARYLAND, COLLEGE PARKInventors: Xiaoping Zhu, Susan Park-Ochsner, Weizhong Li
-
Patent number: 11585815Abstract: The present invention relates to a method for the diagnosis of a benign oncocytoma and a method to differentiate a benign oncocytoma from malignant renal cell carcinoma, a kit for use in these methods, as well as antibody relating thereto, a hybridoma cell capable of producing the same as well as the uses relating thereto.Type: GrantFiled: March 25, 2014Date of Patent: February 21, 2023Assignee: UNIVERSITÄT ZU KOLNInventors: Jochen Fries, Melanie Von Brandenstein
-
Patent number: 11576863Abstract: The present invention provides a method for preparation of a lyophilized formulation of an anti-CD 20 antibody as well as to a lyophilized formulation of an anti-CD 20 antibody, comprising an anti-CD 20 antibody and having a residual moisture content in the range of 1% to 10%. The present invention also relates to the reconstituted formulation obtained by the method described herein, the use of said antibody formulation as a medicament, the use of the lyophilized formulation for the preparation of a medicament and a method of treating a patient.Type: GrantFiled: March 17, 2014Date of Patent: February 14, 2023Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Markus Rast, Wolfgang Ise, Gerhard Becker, Peter Skufca, Henning Gieseler
-
Patent number: 11578324Abstract: The present disclosure provides compositions comprising miR-3132 and one or more pharmaceutical agents that upregulate TNF-related apoptosis-inducing ligand (TRAIL) or activate TRAIL signaling pathway, and methods for treating a cancer comprising administering miR-3132, or a composition comprising miR-3132 and one or more pharmaceutical agents that upregulate TRAIL or activate TRAIL signaling pathway, to a subject.Type: GrantFiled: March 11, 2019Date of Patent: February 14, 2023Assignee: Institute For Cancer ResearchInventors: Amriti R. Lulla, Wafik S. El-Deiry
-
Patent number: 11571636Abstract: The present disclosure relates to, inter alia, a method of quantitating an amount of an antibody molecule from a mixture comprising two or more antibody molecules, comprising separating each of the two or more antibody molecules from the mixture by hydrophobic interaction chromatography high performance liquid chromatography (HIC-HPLC) and quantitating an amount of each antibody molecule, wherein the molecular weight of each antibody molecule is within 15 kDa of any other antibody molecule in the mixture and either each antibody molecule is different from another antibody molecule in the mixture by more than about 0.25 unit on the Kyte & Doolittle hydropathy scale or each of the antibody molecules when nm alone on HIC-HPLC elutes at distinct run time with little overlap from the other antibody molecules in the mixture, or both.Type: GrantFiled: May 17, 2021Date of Patent: February 7, 2023Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Dingjiang Liu, Lin Luo, Long Xu
-
Patent number: 11572414Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates such as those comprising eribulin) thereof that bind to mesothelin are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the compositions provided herein.Type: GrantFiled: November 6, 2020Date of Patent: February 7, 2023Assignee: Eisai R&D Management Co., Ltd.Inventors: Earl F. Albone, Jared Spidel
-
Patent number: 11568959Abstract: Aspects of the disclosure relate to methods for determining whether or a subject is likely to respond to certain adoptive cell therapies (e.g., chimeric antigen receptor (CAR) T-cell therapy, etc.). In some embodiments, the methods comprise the steps of identifying a subject as having a tumor microenvironment (TME) type based upon a molecular-functional (MF) expression signature of the subject, and determining whether or not the subject is likely to respond to a chimeric antigen receptor (CAR) T-cell therapy based upon the TME type. In some embodiments, the methods comprise determining the lymphoma microenvironment (LME) type of a lymphoma (e.g., Diffuse Large B cell lymphoma (DLBCL)) subject and identifying the subject's prognosis based upon the LME type determination.Type: GrantFiled: July 6, 2021Date of Patent: January 31, 2023Assignee: BostonGene CorporationInventors: Nikita Kotlov, Georgy Sagaradze, Alexander Bagaev, Grigorii Nos, Lev Bedniagin, Dmitry Kravchenko, Anna Gribkova
-
Patent number: 11564927Abstract: This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.Type: GrantFiled: November 25, 2019Date of Patent: January 31, 2023Assignee: Verastem, Inc.Inventors: Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
-
Patent number: 11566071Abstract: The presently disclosed subject matter provides antibodies that bind to GPRC5D and methods of using the same.Type: GrantFiled: December 31, 2019Date of Patent: January 31, 2023Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
-
Patent number: 11555076Abstract: The invention provides anti-MIC antibodies and methods of using the same.Type: GrantFiled: October 27, 2017Date of Patent: January 17, 2023Assignee: Genentech, Inc.Inventors: Twyla Noelle Lombana, Christoph Spiess, Jeong Kim, Evangeline Toy, Jill Schartner, Zhengmao Ye, Jack Bevers, III, Ryan Cook, Marissa Matsumoto, Amy Berkley
-
Patent number: 11555072Abstract: The present disclosure relates generally to immunoglobulin-related compositions such as antibodies or antigen binding fragments thereof that can bind to and neutralize the activity of A33 protein. The antibodies of the present technology are useful in methods for detecting and treating an A33-positive cancer in a subject in need thereof.Type: GrantFiled: September 21, 2018Date of Patent: January 17, 2023Assignee: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Zhihao Wu, Hong Xu, Nai-Kong Cheung
-
Patent number: 11548947Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing PSMA, such as prostate tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.Type: GrantFiled: June 21, 2019Date of Patent: January 10, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Lauric Haber, George D. Yancopoulos
-
Patent number: 11548939Abstract: Disclosed herein are methods of treating a subject with an estrogen receptor-positive (ER+) breast cancer comprising obtaining a sample of the breast cancer from the subject; determining a level of E-cadherin in the sample is reduced compared to a control; and administering a therapeutically effective amount of an IGF1R pathway inhibitor and an endocrine therapeutic. Also disclosed herein are methods to treat a cancer in a subject comprising administering a therapeutically effective amount of an IGF1R pathway inhibitor and an E-cadherin inhibitor. Also disclosed are methods to predict the likelihood a subject with a breast cancer will respond therapeutically to a treatment comprising administering an IGF1R pathway inhibitor, the method comprising obtaining a sample of the cancer from the subject; and determining a level of E-cadherin in the sample.Type: GrantFiled: February 26, 2019Date of Patent: January 10, 2023Assignee: University Of Pittsburgh-Of The Commonwealth System Of Higher EducationInventors: Adrian Lee, Alison Nagle, Steffi Oesterreich
-
Patent number: 11548951Abstract: Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) and uses thereof are provided herein and antibodies and pharmaceutical compositions that can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, including reducing proptosis and Clinical Activity Score (CAS) in said subjects, by inhibiting the activity of IGF-1R with such antibodies and compositions.Type: GrantFiled: August 29, 2022Date of Patent: January 10, 2023Assignee: VIRIDIAN THERAPEUTICS, INC.Inventors: Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
-
Patent number: 11541127Abstract: The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.Type: GrantFiled: April 13, 2016Date of Patent: January 3, 2023Assignees: Astellas Pharma, Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbHInventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Maria Kreuzberg, Rita Mitnacht-Kraus, Fabrice Le Gall, Stefan Jacobs
-
Patent number: 11541128Abstract: The present disclosure provides, inter alia, multi-drug Antibody Drug Conjugates (MD-ADCs) and Linking Assembly (LA) Units, that are constructed in a site-specific matter via ‘orthogonal’ deprotection and drug loading. Also provided are, Protected Linking Assembly Units, which allow for ‘orthogonal’ deprotection and construction of MD-ADCs and LA Units of the present disclosure.Type: GrantFiled: December 14, 2017Date of Patent: January 3, 2023Assignee: Seagen Inc.Inventor: Matthew R. Levengood
-
Patent number: 11535678Abstract: The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137. The antibodies and fragments have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.Type: GrantFiled: November 21, 2017Date of Patent: December 27, 2022Assignee: ALLIGATOR BIOSCIENCE ABInventors: Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Laura Von Schantz, Niina Veitonmaki
-
Patent number: 11535670Abstract: Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.Type: GrantFiled: August 14, 2019Date of Patent: December 27, 2022Assignee: HUYABIO International, LLCInventors: Reid P. Bissonnette, Alain Rolland, Mireille Gillings
-
Patent number: 11534445Abstract: Disclosed herein are methods and compositions for enhancing an immune response to a solid tumor in a subject. In some embodiments, a method comprises: (a) administering to the subject a hypoxia-activated bioreductive agent (HABA); (b) inducing hypoxia by (i) administering a hypoxia-inducing agent to the subject or (ii) embolizing one or more blood vessels supplying the solid tumor; and (c) administering an immune checkpoint inhibitor prior to, simultaneously with, or subsequent to step (b) in an amount effective to enhance an immune response to the solid tumor, as compared to an immune response in the absence of the immune checkpoint inhibitor. Kits for use in the disclosed methods are also provided.Type: GrantFiled: April 18, 2018Date of Patent: December 27, 2022Assignee: Teclison LimitedInventor: Ruey-min Lee
-
Patent number: 11534489Abstract: Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.Type: GrantFiled: October 9, 2019Date of Patent: December 27, 2022Assignee: Agency for Science, Technology and ResearchInventors: Cheng-i Wang, Hsueh Ling Janice Oh, Siok Ping Yeo
-
Patent number: 11529371Abstract: Provided are anti-CD33 antibody agents, including anti-CD33 antibody agents in an IgG-scFv format. Various methods and reagents related thereto are also provided, including for example for the detection, prevention, and/or therapeutical treatment of CD33-related diseases, in particular, leukemias such as AML.Type: GrantFiled: April 24, 2018Date of Patent: December 20, 2022Assignee: Memorial Sloan Kettering Cancer CenterInventors: Sayed Shahabuddin Hoseini, Nai-Kong V. Cheung
-
Patent number: 11530266Abstract: The object of the present invention is to provide a humanized or mouse-human chimeric anti-podoplanin antibody or an antibody fragment containing the antigen-binding region thereof, and the object is achieved by providing an isolated humanized or mouse-human chimeric anti-podoplanin antibody which comprises a predetermined amino acid sequence, or an antibody fragment containing the antigen-binding region thereof.Type: GrantFiled: June 14, 2019Date of Patent: December 20, 2022Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCHInventors: Nobuhiko Gyobu, Naoya Fujita, Mamoru Kakino, Ai Kawashima, Shinya Fujihara, Naoki Goda
-
Patent number: 11525005Abstract: Provided are an anti-CD40 antibody, an antigen binding fragment thereof, and a medical use thereof. Also provided are a chimeric antibody and a humanized antibody including a CDR region of the anti-CD40 antibody, a pharmaceutical composition including the human anti-CD40 antibody and the antigen binding fragment thereof, and an application thereof as an anti-cancer drug. In particular, provided are a humanized anti-CD40 antibody, and an application thereof in preparation of a drug to treat a CD40-mediated disease or disorder.Type: GrantFiled: May 31, 2018Date of Patent: December 13, 2022Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.Inventors: Shude Yan, Jiahua Jiang, Qiyue Hu, Lianshan Zhang, Guoqing Cao, Xueming Qian, Fei Teng
-
Patent number: 11525009Abstract: Provided in the present invention is a bispecific antibody which comprises an anti-MUC1 VHH antibody fragment and an anti-CD16 VHH antibody fragment. The antibody fragment used in the present invention is a variable region sequence derived from a heavy chain camelid antibody and has a high binding affinity to the antigen. Antibody fragments recognizing MUC1 and CD16 are constructed in the same antibody molecule by the invention, so that the antibody molecule can specifically bind to MUC1 and CD16 molecules to promote the killing effect of NK cells on MUC1-positive expression cells and has an inhibiting effect on the growth of MUC1-positive tumors. Also provided is a conjugate of the bispecific antibodies, a related pharmaceutical composition and use.Type: GrantFiled: June 21, 2017Date of Patent: December 13, 2022Assignee: BENHEALTH BIOPHARMACEUTIC (SHENZHEN) CO. LTD.Inventors: Haoyang Yu, Zhong Wang, Zhengcheng Li
-
Patent number: 11518799Abstract: The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.Type: GrantFiled: August 1, 2019Date of Patent: December 6, 2022Assignee: Ablynx N.V.Inventors: Catelijne Stortelers, Peter Vanlandschoot, Erik Depla, Jose Melero
-
Patent number: 11519037Abstract: The invention is a method of predicting response to therapy in a colorectal cancer patient, the method comprising analysis of circulating tumor DNA from a patient's sample.Type: GrantFiled: August 7, 2019Date of Patent: December 6, 2022Assignee: ROCHE SEQUENCING SOLUTIONS, INC.Inventors: John Lee, Alexander Lovejoy, John Palma, Ulrich-Peter Rohr, Lijing Yao, Stephanie Yaung
-
Patent number: 11512129Abstract: A TIGIT antibody, an antigen-binding fragment thereof, and a medical use thereof. The present invention relates to a murine antibody, a chimeric antibody, and a humanized antibody comprising a CDR region of the TIGIT antibody, and a pharmaceutical composition comprising the TIGIT antibody and the antigen-binding fragment thereof, and a use thereof as a medicament. In particular, the present invention also relates to a use of a humanized TIGIT antibody for preparing a medicament for the treatment of TIGIT-associated diseases or conditions.Type: GrantFiled: September 28, 2018Date of Patent: November 29, 2022Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.Inventors: Yayuan Fu, Zhuoxiao Cao, Qiyue Hu, Weikang Tao
-
Patent number: 11512351Abstract: Gene expression is measured in a sample of peripheral blood mononuclear cells (PBMCs) obtained from a subject and used to predict organ function recovery. A Function Recovery Potential (FRP) score is assigned to a sample that reflects the measured expression level of the genes identified herein in a direction associated with recovery from organ failure. Treatment of the subject with optimal medical management (OMM) and/or palliative care (PC) is advised when the FRP score is lower than the reference value, and referring the subject for treatment with therapies including—but not limited to—mechanical circulatory support (MCS) surgery, heart transplant (HTx) surgery, or other intervention for advanced heart failure is advised when the FRP score is greater than the reference value. A method for developing an FRP scoring algorithm that predicts a subject's ability to recover from medical intervention for organ failure is also described.Type: GrantFiled: May 29, 2020Date of Patent: November 29, 2022Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Mario Deng, Galyna Bondar
-
Patent number: 11513122Abstract: The invention is concerned with a method of predicting response to a PD-1 axis inhibitor such as anti-PD-L1 antibody by determining the abundance of dendritic cells (DCs) in a tumor tissue sample. The abundance of DCs characterized by enhanced expressions of XCR1, IRF8, BATF3 and FLT3 predicts clinical response to the PD-L1 blockade 5 treatment.Type: GrantFiled: March 25, 2019Date of Patent: November 29, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Christian Klein, Maud Léa Mayoux, Andreas Roller, Wei Xu
-
Patent number: 11505606Abstract: The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.Type: GrantFiled: June 20, 2017Date of Patent: November 22, 2022Assignee: TeneoBio, Inc.Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
-
Patent number: 11505609Abstract: The present invention, in the field of bioengineering and biotechnology, relates to a method for preparing a recombinant antibody with a unique glycan profile produced by a genome-edited CHO host cell. Specifically, according to a method of the present invention, the TALEN technology is used to edit the FUT8 gene in CHO cells that have been adapted for serum-free suspension growth. The edited CHO host cells can produce recombinant antibodies with a unique glycan profile. The unique glycan profile can be characterized by non-fucosylated N-linked oligosaccharide chains of the antibodies, extremely low N-glycosylation heterogeneity and uniform carbohydrate chains. The antibody prepared by the method of the invention exhibit significantly increased ADCC and greater stability.Type: GrantFiled: August 10, 2018Date of Patent: November 22, 2022Assignee: Bio-Thera Solutions, Ltd.Inventors: Chao Qin, Yuanqing Zhou, Cuizhen Xiao
-
Patent number: 11505592Abstract: The serotonin receptor 5HT2A (5HT2aR) and membrane NADPH oxidases (NOX enzymes) are found to be a target of autoantibodies present in Multiple Sclerosis patients. The present invention refers to peptides comprised in the extracellular regions of the human 5HT2aR and/or NOXs for diagnosis and therapy of Multiple Sclerosis.Type: GrantFiled: April 24, 2020Date of Patent: November 22, 2022Assignee: PRINDEX S.R.L.Inventors: Roberto Paterno, Mariarosaria Santillo, Vittorio Enrico Avvedimento, Luigi Michele Pavone
-
Patent number: 11505574Abstract: The invention provides compositions and methods for preventing or treating cancer in a subject. In some embodiments, the compositions comprise isolated peptides and/or isolated oligonucleotides. In other embodiments, peptides of the present invention are conjugated with cell-penetrating peptides. Vectors, cells, and kits for preventing or treating cancer are also provided herein.Type: GrantFiled: May 24, 2019Date of Patent: November 22, 2022Assignee: The Regents of the University of CaliforniaInventors: Xinbin Chen, Christopher A. Lucchesi, Jin Zhang
-
Patent number: 11499249Abstract: Libraries of immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind.Type: GrantFiled: November 22, 2019Date of Patent: November 15, 2022Assignee: F-Star Therapeutics LimitedInventors: Gottfried Himmler, Florian Ruker, Gordana Wozniak-Knopp
-
Patent number: 11498959Abstract: Pharmaceutical formulations for anti-CGRP antibodies, and methods of using the same, are provided which are useful as treatment for migraines, episodic headaches, chronic headaches, chronic cluster headaches, and episodic cluster headaches.Type: GrantFiled: June 8, 2016Date of Patent: November 15, 2022Assignee: Eli Lilly and CompanyInventor: Anant N Sharma
-
Patent number: 11498964Abstract: The invention provides a bispecific antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention provides a nucleic acid encoding the antibody construct, a vector comprising the nucleic acid and a host cell transformed or transfected with the vector. Furthermore, the invention provides a process for the production of the bispecific antibody construct, a medical use of the antibody construct and a kit comprising the antibody construct. The bispecific antibody construct may be useful in the treatment of melanoma.Type: GrantFiled: July 20, 2018Date of Patent: November 15, 2022Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.Inventors: Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, M. Shawn Jeffries, Chadwick Terence King, Brian Mingtung Chan, Peter Kufer, Ralf Lutterbüse, Tobias Raum, Patrick Hoffmann, Doris Rau, Roman Kischel, Bryan Lemon, Holger Wesche
-
Patent number: 11499973Abstract: Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided. The methods may include obtaining a sample from the subject, determining an expression level of at least one biomarker selected from the group consisting of VEGF-D and PlGF in a sample from the subject, comparing the expression level of the biomarker in the sample to a reference level of the biomarker, and predicting the responsiveness of the cancer to treatment with the cancer therapy including a VEGF targeting agent. Optionally, the methods may further include administering a VEGF target agent and/or an anticancer or chemotherapy agent to the subject. Additional methods of prognosing and treating a cancer in a subject are also provided.Type: GrantFiled: May 17, 2017Date of Patent: November 15, 2022Assignee: Duke UniversityInventors: Andrew Nixon, Chris Brady, Yingmiao Liu, Herbert Hurwitz, Kouros Owzar, Alexander Sibley, Chen Jiang, Ace Hatch, Mark Starr
-
Patent number: 11497767Abstract: Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. Further, anti-inflammatory cytokine release may be reduced. In certain instances, compositions may include additional agents.Type: GrantFiled: October 7, 2019Date of Patent: November 15, 2022Assignee: ENLIVEX THERAPEUTICS R&D LTDInventors: Shai Novik, Dror Mevorach
-
Patent number: 11498977Abstract: The present invention provides a method for production of stable and highly specific heterodimeric immunoglobulin constructs, e.g., bispecific antibodies, retaining desirable properties of native IgG and lacking undesirable heavy chain-light chain mispairing, that can simultaneously bind two target molecules and are more potent in the treatment of complex diseases.Type: GrantFiled: September 28, 2017Date of Patent: November 15, 2022Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Jiawang Liu, Nanmeng Song, Dongge Yang, Yaping Yang, Maengsup Kim
-
Patent number: 11498971Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a BCMA monoclonal antibody, conferring specific immunity against BCMA positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas, multiple myeloma and leukemia.Type: GrantFiled: May 8, 2019Date of Patent: November 15, 2022Assignee: CellectisInventor: Roman Galetto
-
Patent number: 11491247Abstract: The present invention relates to a method for treating cancer. This method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent comprising a second targeting component coupled to a second cancer therapeutic component. The first and second targeting components have different biodistributions and/or pharmacokinetics. The first and second agents are administered to a subject having cancer to treat the cancer. Also disclosed is a combination therapeutic comprising the first and second agents.Type: GrantFiled: May 2, 2018Date of Patent: November 8, 2022Assignee: CORNELL UNIVERSITYInventor: Neil H. Bander
-
Patent number: 11492415Abstract: The present invention relates to a polypeptide including an Fc variant produced by substituting a portion of the amino acid sequence of the Fc domain of a human antibody with a different amino acid sequence. The present invention also relates to an antibody including the polypeptide. The Fc variant can find application in a wide range of antibodies and Fc-fusion constructs. In one aspect, the antibody or Fc fusion construct of the present invention is a therapeutic, diagnostic or laboratory reagent, preferably a therapeutic reagent. The Fc variant is suitable for use in the treatment of cancer because its in vivo half-life can be maximized by optimization of the portion of the amino acid sequence. The antibody or Fc fusion construct of the present invention is used to kill target cells that bear a target antigen, for example cancer cells. Alternatively, the antibody or Fc fusion construct of the present invention is used to block, antagonize or agonize a target antigen.Type: GrantFiled: April 6, 2018Date of Patent: November 8, 2022Assignees: KOOKMIN UNIVERSITY INDUSTRY ACADEMY, OSONG MEDICAL INNOVATION FOUNDATIONInventors: Sang Taek Jung, Sanghwan Ko, Tae Gyu Lee, So Young Choi, Soo Han Lee, Myung Ho Sohn, Su Jin Kim, So Ra Park, Jong Shik Park, Ju Hyeon Lim
-
Patent number: RE49477Abstract: A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the ?2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.Type: GrantFiled: October 2, 2019Date of Patent: March 28, 2023Assignee: Thomas Jefferson UniversityInventors: Andrzej Fertala, Andrzej Steplewski